Knockdown of S6k1 impedes the self-renewal potential of murine hematopoietic stem cells, and depletion of S6k1 shows prolonged survival in mice, suggesting a potential strategy for myeloid malignancy treatment [56]. This evidence concerns the gene RPS6KB1 and myeloid neoplasm.